Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | DAO | P14920 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | BCL2 | P10415 | 2/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.49 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stilbostemin B SCHEMBL31039665 | 0.82 | IGF1R (0.52) | IGF1RALOX15DAOBCL2BCL2L1 | |
| SCHEMBL716875 | 0.81 | ESR1 (0.67) | IGF1RALOX15L3MBTL1POLBTAAR1 | |
| SCHEMBL278794 | 0.81 | IDH1 (0.65) | IGF1RALOX15BCL2BCL2L1IDH1 | |
| SCHEMBL13903972 | 0.79 | TDP1 (0.46) | IGF1RALOX15DAOBCL2BCL2L1 | |
| SCHEMBL9744485 | 0.79 | ALOX15 (0.84) | IGF1RALOX15IDH1TAAR1TDP1 | |
| SCHEMBL4648373 | 0.79 | ALDH1A1 (0.58) | ALOX15CYP2A6HTR2ASMN1; SMN2TAAR1 | |
| Hydrogen Peroxide SCHEMBL10839871 | 0.79 | TDP1 (0.71) | ALOX15CYP2A6HTR2ASMN1; SMN2TAAR1 | |
| Hydrogen Peroxide SCHEMBL10839772 | 0.79 | TDP1 (0.71) | ALOX15CYP2A6HTR2ASMN1; SMN2TAAR1 | |
| SCHEMBL22149262 | 0.79 | GAA (0.56) | IGF1RALOX15DAOBCL2L1MCL1 | |
| SCHEMBL31540969 | 0.79 | IGF1R (0.53) | IGF1RALOX15DAOBCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410116-B2 | Compounds and use thereof in methods of treatment | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-09-09 | — | — | US | disclosed |
| US-20240002326-A1 | COMPOUNDS AND USE THEREOF IN METHODS OF TREATMENT | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-01-04 | — | — | US | disclosed |
| US-20230100768-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-03-30 | — | — | US | disclosed |
| US-11434190-B2 | Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-09-06 | — | — | US | disclosed |
| US-20200188878-A1 | MOLECULARLY IMPRINTED POLYMERS | MONASH UNIVERSITY (AU) | 2020-06-18 | — | — | US | disclosed |
| US-20200188878-A1 | MOLECULARLY IMPRINTED POLYMERS | MONASH UNIVERSITY (AU) | 2020-06-18 | — | — | US | disclosed |
| US-20190337880-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-11-07 | — | — | US | disclosed |
| US-20190337880-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-11-07 | — | — | US | disclosed |
| US-20160288090-A1 | MOLECULARLY IMPRINTED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-10-06 | — | — | US | disclosed |
| US-20160288090-A1 | MOLECULARLY IMPRINTED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-10-06 | — | — | US | disclosed |
| US-20160288090-A1 | MOLECULARLY IMPRINTED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-10-06 | — | — | US | disclosed |
| US-20120052757-A1 | MOLECULARLY IMPRINTED POLYMERS | MONASH UNIVERSITY (AU) | 2012-03-01 | — | — | US | disclosed |
| US-20120052757-A1 | MOLECULARLY IMPRINTED POLYMERS | MONASH UNIVERSITY (AU) | 2012-03-01 | — | — | US | disclosed |
| US-20120052757-A1 | MOLECULARLY IMPRINTED POLYMERS | MONASH UNIVERSITY (AU) | 2012-03-01 | — | — | US | disclosed |
| EP-2391658-A1 | MOLECULARLY IMPRINTED POLYMERS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010085851-A1 | MOLECULARLY IMPRINTED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010085851-A1 | MOLECULARLY IMPRINTED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2010-08-05 | — | — | WO | disclosed |
| US-5087548-A | POSITIVE TYPE RADIATION-SENSITIVE RESIN COMPOSITION | JAPAN SYNTHETIC RUBBER CO., INC. (JP) | 1992-02-11 | — | — | US | disclosed |
| EP-0227487-A2 | Positive type radiation-sensitive resin composition | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337880-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | SOX18, PROX1, RUNX1 | IGF1R 2251/4885ALOX15 2078/4885DAO 3710/4885 |
| US-11434190-B2 | Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases | SOX18, PROX1, RUNX1 | IGF1R 2251/4885ALOX15 2078/4885DAO 3710/4885 |
| US-20160288090-A1 | MOLECULARLY IMPRINTED POLYMERS | IPMK, MPI, PIM3 | IGF1R 147/4885ALOX15 2317/4885DAO 2708/4885 |
| US-20230100768-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | SOX18, PROX1, RUNX1 | IGF1R 2504/4885ALOX15 1764/4885DAO 3586/4885 |
| US-20120052757-A1 | MOLECULARLY IMPRINTED POLYMERS | IPMK, MPI, PIM3 | IGF1R 147/4885ALOX15 2317/4885DAO 2708/4885 |
| US-20200188878-A1 | MOLECULARLY IMPRINTED POLYMERS | IPMK, MPI, PIM3 | IGF1R 147/4885ALOX15 2317/4885DAO 2708/4885 |
| US-12410116-B2 | Compounds and use thereof in methods of treatment | SOX18, PROX1, RUNX1 | IGF1R 2869/4885ALOX15 2048/4885DAO 3538/4885 |
| US-20240002326-A1 | COMPOUNDS AND USE THEREOF IN METHODS OF TREATMENT | SOX18, PROX1, RUNX1 | IGF1R 2869/4885ALOX15 2048/4885DAO 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.